Apalutamide plus ADT improves pathological response and metastasis-free survival in high-risk prostate cancerTrial shows apalutamide improves outcomes for high-risk prostate cancer

This Phase 3 randomized controlled trial evaluated the efficacy and safety of perioperative treatment in 2109 patients with newly diagnosed high-risk localized or locally advanced prostate cancer. The study design focused on patients undergoing radical prostatectomy with pelvic lymph-node dissection to determine if the addition of apalutamide to androgen deprivation therapy (ADT) improved oncologic outcomes compared to ADT alone.

The intervention group received ADT plus apalutamide at a dose of 240 mg per day for 6 cycles of 28 days each, administered both before and after radical prostatectomy with pelvic lymph-node dissection. The comparator group received ADT plus a placebo following the same 6-cycle, 28-day duration protocol. The study followed patients for a median duration of 61.7 months.

The primary outcome was a composite of pathological complete response or minimal residual disease (defined as a pathological stage of ypT2 or lower, with a tumor size of less than or equal to 5 mm in the greatest dimension) and metastasis-free survival. Results showed that the apalutamide group achieved a pathological complete response or minimal residual disease rate of 8.9% compared to 1.0% in the placebo group. This finding was associated with an odds ratio of 10.17 (95% CI, 5.27 to 19.64; P<0.001). Additionally, the 5-year metastasis-free survival rate was 78.2% in the apalutamide group versus 73.5% in the placebo group (hazard ratio, 0.80; 95% CI, 0.67 to 0.96; P=0.02).

Secondary outcomes further supported the efficacy of the intervention. The apalutamide group showed significantly favored results for event-free survival (P<0.001), time to the first subsequent treatment (P<0.001), and time to distant metastasis (P<0.001) compared to the placebo group. These results indicate a statistically significant advantage for patients receiving the combination therapy across multiple clinical milestones.

Regarding safety and tolerability, Grade 3 or 4 adverse events occurred in 39.6% of the apalutamide group and 31.0% of the placebo group. The difference in these adverse events was primarily driven by a higher incidence of rash in the apalutamide group. Specific data regarding serious adverse events, treatment discontinuations, or general tolerability metrics were not reported.

These results contribute to the understanding of perioperative management in high-risk prostate cancer. While the study demonstrates a clear statistical advantage for apalutamide in the primary composite outcome and several secondary endpoints, the primary outcome is a composite measure. The study was funded by Johnson & Johnson.

Methodological limitations include the use of a composite primary endpoint and the lack of reported data on serious adverse events or specific tolerability metrics. Clinical implications suggest that perioperative treatment with ADT plus apalutamide is associated with improved oncologic outcomes for radical prostatectomy in patients with high-risk localized or locally advanced prostate cancer compared to ADT plus placebo. Questions remain regarding the long-term impact of the higher incidence of rash and the specific clinical impact of the difference in metastasis-free survival rates over longer follow-up periods.